biotech · Fabry Disease · Bioequivalence · PLX
Protalix Biotherapeutics
Protalix BioTherapeutics
Protalix Biotherapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
- Founded
- 1994
- Employees
- 197
- Programs
- 21
- Drugs
- 14
- Patents
- 22
Protalix Biotherapeutics projects
9 ClinicalTrials.gov programs sponsored by Protalix Biotherapeutics.
Protalix Biotherapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AIR DNase™
Protalix BioTherapeutics
Cystic Fibrosis
1 trial -
Ibuprofen-PC
Protalix BioTherapeutics
Osteoarthritis
1 trial -
Naproxen
Protalix BioTherapeutics
Healthy Volunteers
1 trial -
OPRX-106
Protalix BioTherapeutics
Ulcerative Colitis
1 trial -
PL2200
Protalix BioTherapeutics
Gastroduodenal Ulceration
1 trial -
PL3100
Protalix BioTherapeutics
Gastroduodenal Ulcerations
1 trial -
PRX-112
Protalix BioTherapeutics
Gaucher Disease
2 trials -
PRX-115
Protalix BioTherapeutics
Gout
2 trials -
acetylsalicylic acid
Protalix BioTherapeutics
Upper Gastrointestinal Mucosal Damage
1 trial
Frequently asked questions
How many clinical projects does Protalix Biotherapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.